BIOATLA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.43 USD | -3.95% |
|
-27.46% | -1.22% |
| Mar. 27 | HC Wainwright Adjusts BioAtla's Price Target to $7 From $10, Maintains Buy Rating | MT |
| Mar. 26 | Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024 |
Presenter SpeechLut Ming Cheng (Analysts)Good afternoon, everyone. Thank you so much for joini...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Companyâs product candidates include Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), BA3071, and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. The BA3071 is a potential therapeutic for multiple solid tumor types, including soft tissue and bone sarcoma, and non-small cell lung cancer (NSCLC). BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Calendar
2024-05-08
- Q1 2024 Earnings Release (Projected)
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.43
USD
Average target price
11.5
USD
Spread / Average Target
+373.25%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.22% | 117M | |
| -1.82% | 41.35B | |
| +41.42% | 40.38B | |
| +2.56% | 39.05B | |
| -12.11% | 26.67B | |
| +3.09% | 24.07B | |
| -24.16% | 18.36B | |
| +22.12% | 11.6B | |
| -3.74% | 11.68B | |
| +7.75% | 11.15B |
- Stock Market
- Equities
- BCAB Stock
- News BioAtla, Inc.
- Transcript : BioAtla, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 03
